Recent Comments
- LB on The final House report on COVID
- Joy Smith on The Declaration of Pandemics
- Linnea Comstock on The Declaration of Pandemics
- Lance W Richardson on The Declaration of Pandemics
- Sarah on The Declaration of Pandemics
Most Viewed Posts
- Exclusive: Why the COVID “mRNA” vaccines are actually DNA gene therapies that must be removed from the market (23,611)
- Pfizer admits in federal court that the COVID gene therapies were never approved through the FDA (17,638)
- New treatment paradigm for C. Diff colitis (16,050)
- The Healthcare Channel hits 10 (15,502)
- Gordon Guyatt, MD: Update on the problem of clinical trials being stopped early to inflate efficacy of drugs (15,302)
- How the FDA regulates compounding pharmacies (15,132)
- I discuss the handling of the COVID-19 outbreak on The Joe Piscopo radio show (14,978)
- The Who’s Teen Cancer Lounge at Sloan Kettering opens (10,947)
- The new CDC guidelines for prescribing opioid pain pills (10,419)
- Exclusive: Michael Bloomberg took control of Johns Hopkins with his billions. Then, death rates skyrocketed at a children’s hospital. (10,279)
Pages
Categories
- – Biotech
- – Generics
- – JAMA
- – Medical Devices
- – NEJM
- – Opinion
- – Pharma
- – Policy
- – Reviews, books, devices
- – The Weekly Summary
- Bariatric surgery
- Cardiac surgery
- Cardiology
- Dermatology
- Diabetes and endocrinology
- Emergency medicine
- Gastroenterology and liver
- General surgery
- Genetics
- Geriatrics
- Infectious disease
- Internal Medicine
- Neurology
- Neurosurgery
- Nutrition
- Obstetrics and Gynecology
- Oncology
- Ophthalmology
- Orthopedic surgery
- Pediatrics
- Plastic surgery
- Primary care medicine
- Psychology Psychiatry
- Pulmonology
- Radiology
- Rheumatology
- Spine surgery
- Sports medicine
- Transplant surgery
- Trauma Surgery
- Uncategorized
- Urology
- Vascular Surgery
- Z Medical centers
- Baylor
- Boston University
- Cedars Sinai
- Cleveland Clinic
- Columbia
- Cornell
- Duke
- Emory
- George Washington Univ
- Harvard
- Henry Ford
- Iowa State
- Johns Hopkins
- Mayo Clinic
- McMaster University
- Medical University of South Carolina
- Memorial Sloan-Kettering
- Michigan
- National Jewish Health
- NYU
- Ohio State
- Oregon Health and Science University
- UC Davis
- UC San Francisco
- UCLA
- Univ Kentucky
- Univ Maryland
- Univ Miami
- Univ Michigan
- Univ of Louisville
- Univ Texas
- VA Walter Reed
- Vanderbilt
- VCU
- Washington University
- Yale
Category Archives: – Biotech
The only thing we have to fear…is fear itself
March 13, 2020- by Steven E. Greer, MD Holy cow. The PGA Tour cancelled the Players Championship due to fears over the coronavirus.
Pfizer documents show vaccine causes high fetal death rates
February 3, 2022- by Steven E. Greer, MD
India, Mexico, and El Salvador distribute ivermectin to citizens in free COVID kits
January 20, 2022- by Steven E. Greer, MD As all hospitals in the U.S. refuse to administer lifesaving early treatments for the SARS-CoV-2 coronavirus,
What you need to know about the SARS-CoV-2 coronavirus vaccines
Update March 22, 2021- by Steven E. Greer, MD Tucker Carlson interviewed a surgeon who stated what I have known for many months. The signal
Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Infectious disease, Internal Medicine, NIH
Leave a comment
Sen. Ron Johnson on the need for early treatment of the Wuhan coronavirus
December 13, 2020- by Steven E. Greer, MD This is straight from my book, Tony’s Virus, chapters 8 and chapter 10.
The “surge in new Wuhan virus cases” is great news
June 26, 2020- by Steven E. Greer, MD I called it, once again. On June 9th, I wrote, “This unprecedented communist-party-like anarchy in
Are there any medications to treat coronavirus?
(Also: How infectious and lethal is this Coronavirus COVID-19 compared to regular “flu”?) February 27, 2020- by Steven E. Greer, MD Gilead makes a not-yet-approved antiviral drug called remdisivir and it is being tested right
Posted in - Biotech, - Opinion, - Pharma, - Policy, CDC, Congress, FDA, Geriatrics, Infectious disease, Internal Medicine, NIH, Primary care medicine
2 Comments
60 Minutes creates another publicist-paid puff-piece for an unethical medical researcher
December 8, 2019- by Steven E. Greer, MD CBS’ 60 Minutes featured an extremely unethical PhD medical researcher at Harvard named George
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
February 27, 2017- interviewed by Steven E. Greer, MD We interviewed Joaquim Bellmunt, MD, PhD, the Director of the Bladder Cancer Center at Dana-Farber,
Preventing HIV infection
July 28, 2014- Interviewed by Steven E. Greer, MD Rajesh Tim Gandhi, MD of the Massachusetts General Hospital discusses the NEJM review paper he co-wrote
Paul Richardson, MD: Current Therapies for Multiple Myeloma
December 15, 2015- Interviewed by Steven Greer, MD Dr. Paul Richardson, Clinical Director of the Multiple Myeloma Center at Harvard’s Dana-Farber
Posted in - Biotech, - Pharma, Harvard, Oncology
Leave a comment
Triple Therapy for Cystic Fibrosis
October 18, 2018- interviewed by Steven E. Greer, MD
BRAF and MEK combos for melanoma
Update October 1, 2015- The FDA approved the use of two drugs, Opdivo and Yervoy, to treat metastatic melanoma, as we first discussed with Dr. Ribas last year.
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
Google wants your medical records
December 19, 2013- Interviewed by Steven E. Greer, MD In Part 3 of our interview with Robert Klitzman, MD, ethics professor at Columbia University,
Google’s Larry Page wants your medical records to be public for “research”
March 20, 2014-By Steven E. Greer, MD Charlie Rose interviewed Google founder Larry Page at the 2014 TED conference. During the talk, Mr.
Posted in - Biotech, - Medical Devices, - Opinion, Congress, Genetics
Leave a comment
Review of immunotherapy and targeted therapy
June 17, 2016- interviewed by Steven E. Greer, MD We interviewed Siwen Hu-Lieskovan MD, PhD of UCLA, an expert with immunotherapies for melanoma, to go over the
Posted in - Biotech, - Pharma, Oncology, UCLA
Leave a comment
The Year in Review: 2018
December 29, 2018- by Steven E. Greer, MD The biggest stories this year related
Insurance companies are not paying for Repatha and Praluent
Update November 2, 2018- Amgen slashed the annual cost of this drug to $6,000.
Ocrelizumab (Ocrevus) versus Placebo in Primary Progressive Multiple Sclerosis
January 31, 2017- Interviewed by Steven E. Greer, MD
Posted in - Biotech, - NEJM, - Pharma, Neurology, Univ Texas
Leave a comment
KIT inhibition by Gleevec (imatinib) for severe asthma
May 26, 2017- Interviewed by Steven E. Greer, MD Novartis’ Gleevec (imatinib) was approved in the U.S. in 2001 to treat leukemia. Now, researchers
Posted in - Biotech, - NEJM, - Pharma, National Jewish Health, Pulmonology
Leave a comment